+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody-siRNA Drug Conjugates Market - Global Forecast 2025-2030- Product Image
Antibody-siRNA Drug Conjugates Market - Global Forecast 2025-2030- Product Image
Sale

Antibody-siRNA Drug Conjugates Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6136891
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Antibody-siRNA drug conjugates are redefining targeted therapies by combining precise antibody delivery with advanced gene-silencing technology. This evolving market is unlocking new possibilities, from oncology to rare genetic disorders, as organizations respond to growing demand for specificity, minimized off-target effects, and innovation in complex biopharmaceuticals.

Market Snapshot: Antibody-siRNA Drug Conjugates Market

The Antibody-siRNA Drug Conjugates Market grew from USD 1.13 billion in 2024 to USD 1.25 billion in 2025. It is expected to continue growing at a CAGR of 11.14%, reaching USD 2.14 billion by 2030.

Scope & Segmentation

This report categorizes the antibody-siRNA drug conjugates market across multiple dimensions, emphasizing technology, application, and market reach:

  • Target Antibody Types: Antibody fragments (Fab, scFv), bispecific antibodies, monoclonal antibodies.
  • Conjugation Chemistry: Cleavable linkers, non-cleavable linkers, site-specific conjugation.
  • Route of Administration: Intravenous (IV), subcutaneous (SC).
  • End Users: Biotechnology companies, contract research organizations, pharmaceutical companies.
  • Therapeutic Areas: Genetic disorders (common and rare), infectious diseases (bacterial and viral), neurological disorders, oncology (hematological malignancies and solid tumors).
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: AbbVie Inc., Avidity Biosciences Inc., Biointron Biological Inc., CD Bioparticles, Dyne Therapeutics, Inc., Sirnaomics, Inc., Tallac Therapeutics, Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc.

Key Takeaways for Senior Decision-Makers

  • Integration of antibody engineering and gene-silencing siRNA platforms is accelerating the emergence of highly targeted therapies that address complex diseases with new mechanisms of action.
  • Strategic partnerships between antibody engineers, RNA experts, and clinical leaders are expediting proof-of-concept development, lead candidate selection, and the adoption of robust delivery models.
  • Market evolution is strongly supported by advances in nanotechnology, bioconjugation techniques, and computational biology, leading to improved molecular control and enhanced therapeutic potential of antibody-siRNA conjugates.
  • Segment diversification, especially in antibody formats and conjugation chemistries, allows organizations to customize therapeutic approaches for specific clinical challenges, from deep tumor targeting to rapid systemic clearance.
  • Expanding manufacturing infrastructure in Asia-Pacific and North America is shaping competitive dynamics, while localized regulatory strategies enable responsive clinical and commercial operations tailored to each geography.
  • Ongoing collaboration and data-sharing consortia are standardizing drug-to-antibody ratio measurements and safety assessments, streamlining industry-wide progress and supporting regulatory alignment.

Tariff Impact on Supply Chains and Strategy

Recent U.S. tariffs on biopharmaceutical materials have introduced additional cost layers, affecting procurement for antibody production, linker synthesis, and oligonucleotide components. Companies are reevaluating supplier networks and leaning toward partnerships with domestic contract development and manufacturing organizations to mitigate cost increases and logistical complexities. Joint ventures now often include explicit arrangements to share or offset tariff liabilities, supporting supply chain resiliency.

Methodology & Data Sources

The report’s insights stem from comprehensive secondary research, including peer-reviewed publications, regulatory guidance, and patent reviews. Primary interviews with experts in antibody engineering, RNA therapeutics, regulatory compliance, and supply chain management complement this analysis, ensuring robust qualitative and quantitative validation.

Why This Antibody-siRNA Drug Conjugates Report Matters

  • Enables targeted investment and resource allocation across technology platforms, regions, and therapeutic segments.
  • Equips decision-makers with actionable intelligence for navigating technological, regulatory, and supply chain complexities in the biopharmaceutical landscape.
  • Supports faster, informed market entry and competitive differentiation by identifying leading players and the latest collaborative trends.

Conclusion

Antibody-siRNA drug conjugates represent a transformative advancement in targeted medicine. Strategic alliances, platform innovation, and adaptive supply chain management are shaping the trajectory of this dynamic sector. Senior leaders can leverage these insights to drive sustainable growth in a changing therapeutic landscape.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in tumor-targeting antibodies improving siRNA delivery efficacy in solid tumors
5.2. Emergence of dual payload antibody-siRNA conjugates tackling multidrug-resistant cancer cells
5.3. Optimization of linker technologies driving enhanced stability and release profiles in antibody-siRNA conjugates
5.4. Integration of biodegradable polymeric carriers for controlled siRNA release in ADC platforms
5.5. Adoption of cryo-EM structural analysis for rational design of antibody-siRNA conjugation sites
5.6. Development of bispecific antibodies for co-delivery of siRNA and immunomodulators to tumor microenvironment
5.7. Progress in endosomal escape strategies boosting cytosolic siRNA availability in ADC therapies
5.8. Regulatory guidelines evolving to standardize antibody-siRNA conjugate characterization and safety testing
5.9. Implementation of artificial intelligence in predicting optimal conjugation sites for antibody-siRNA drugs
5.10. Strategic partnerships between biotech firms and pharma to accelerate clinical pipelines of antibody-siRNA conjugates
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antibody-siRNA Drug Conjugates Market, by Target Antibody Type
8.1. Introduction
8.2. Antibody Fragments
8.2.1. Fab
8.2.2. scFv
8.3. Bispecific Antibody
8.4. Monoclonal Antibody
9. Antibody-siRNA Drug Conjugates Market, by Conjugation Chemistry
9.1. Introduction
9.2. Cleavable Linker
9.3. Non Cleavable Linker
9.4. Site-Specific Conjugation
10. Antibody-siRNA Drug Conjugates Market, by Route of Administration
10.1. Introduction
10.2. Intravenous (IV)
10.3. Subcutaneous (SC)
11. Antibody-siRNA Drug Conjugates Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.3. Contract Research Organizations
11.4. Pharmaceutical Companies
12. Antibody-siRNA Drug Conjugates Market, by Therapeutic Area
12.1. Introduction
12.2. Genetic Disorders
12.2.1. Common Genetic Diseases
12.2.2. Rare Genetic Diseases
12.3. Infectious Diseases
12.3.1. Bacterial Infections
12.3.2. Viral Infections
12.4. Neurological Disorders
12.5. Oncology
12.5.1. Hematological Malignancies
12.5.2. Solid Tumors
13. Americas Antibody-siRNA Drug Conjugates Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antibody-siRNA Drug Conjugates Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Antibody-siRNA Drug Conjugates Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Avidity Biosciences Inc.
16.3.3. Biointron Biological Inc.
16.3.4. CD Bioparticles
16.3.5. Dyne Therapeutics, Inc.
16.3.6. Sirnaomics, Inc.
16.3.7. Tallac Therapeutics, Inc.
16.3.8. GlaxoSmithKline plc
16.3.9. Regeneron Pharmaceuticals Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIBODY-SIRNA DRUG CONJUGATES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTIBODY-SIRNA DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTIBODY-SIRNA DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHAI
FIGURE 26. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHSTATISTICS
FIGURE 27. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHCONTACTS
FIGURE 28. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIBODY-SIRNA DRUG CONJUGATES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY FAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY FAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SCFV, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SCFV, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE LINKER, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE LINKER, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SITE-SPECIFIC CONJUGATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SITE-SPECIFIC CONJUGATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COMMON GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COMMON GENETIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 113. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 115. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 116. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 117. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 118. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 119. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 124. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 125. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 126. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 127. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 128. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 129. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 130. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 136. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 137. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 142. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 143. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 144. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 147. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 223. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 224. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 225. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 226. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 227. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 228. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 229. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 234. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 235. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 236. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 237. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 238. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 239. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 240. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 241. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 242. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 243. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 244. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 245. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 246. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 247. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 252. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 253. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 254. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 255. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 256. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 257. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 277. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 278. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 279. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
TABLE 280. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
TABLE 281. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 282. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 283. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 288. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 289. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 290. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 291. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 292. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 293. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 294. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 295. SPAIN ANTIBODY-SIRNA DRUG CONJUGATES MARKET

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antibody-siRNA Drug Conjugates market report include:
  • AbbVie Inc.
  • Avidity Biosciences Inc.
  • Biointron Biological Inc.
  • CD Bioparticles
  • Dyne Therapeutics, Inc.
  • Sirnaomics, Inc.
  • Tallac Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.25 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.14 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 87 Pages
  • Global
From
2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
siRNA/miRNA Synthesis Service Market - Global Forecast 2025-2030 - Product Image

siRNA/miRNA Synthesis Service Market - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
RNA-based Therapeutics - Global Strategic Business Report - Product Image

RNA-based Therapeutics - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
RNA Interference- Pipeline Insight, 2025 - Product Image

RNA Interference- Pipeline Insight, 2025

  • Drug Pipelines
  • 204 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.